RJA
BEAM icon

Raymond James & Associates’s Beam Therapeutics BEAM Stock Holding History

Raymond James & Associates’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,163
Closed -$239K – 4036
2022
Q1 		$239K Buy
4,163
+1,263
+44% +$82.8K ﹤0.01% 3566
2021
Q4 		$231K Buy
+2,900
New +$248K ﹤0.01% 3606
2021
Q3 		– Sell
-2,436
Closed -$314K – 4122
2021
Q2 		$314K Buy
+2,436
New +$194K ﹤0.01% 3409

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Raymond James & Associates's BEAM Position: Q2 2022 in Review

Raymond James & Associates sold out of Beam Therapeutics (BEAM) in Q2 2022, closing a stake of 4,163 shares — an estimated $239K sold.

Raymond James & Associates first reported a position in BEAM in Q2 2021 and held it in 3 quarters. The position peaked at $314K in Q2 2021. 205 funds tracked by Wall St. Rank hold BEAM as of Q2 2022.

  • Raymond James & Associates reported no remaining Beam Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Raymond James & Associates sold 4,163 Beam Therapeutics shares in Q2 2022, an estimated $239K.
  • Raymond James & Associates first reported a position in Beam Therapeutics in Q2 2021 and held it in 3 quarters.
  • Raymond James & Associates's Beam Therapeutics position peaked at $314K in Q2 2021.
  • 205 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2022.

Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.